Advance Research Series
Next-Generation iPSC Models Stem From Ncardia
iPSC-Hematopoietic Stem Cells
Identity:
- High-purity iPSC-derived hematopoietic stem/progenitor cells (≥70% CD34+/CD45+/CD43+)
- Stepwise differentiation confirmed by surface marker expression and flow cytometry
- Suitable for applications in hematopoiesis research, immunology, disease modeling and drug testing
|
Identity Markers |
≥ 70% CD34+/CD45+/CD43+ |
|
Size |
≥ variable formats |
|
Quality Control |
Cell count, Viability, Identity (FACS), Mycoplasma |
|
Format |
Cryopreserved cells |
|
Donor |
Female |
|
Reprogramming method |
Non-viral |
|
Shipping conditions |
Dry shipper, -180°C to -135°C |
|
Storge conditions |
Vapor phase of liquid nitrogen |
Specifications:
- Our HSCs show efficient differentiation, with >97% CD34+ cells at early stages
- Flow cytometry confirms sequential acquisition of CD43 and CD45, resulting in >90% CD34+/CD43+ and >90% CD34+/CD45+ definitive hematopoietic populations
- This progressive enrichment is maintained across batches and is stable post-thaw, ensuring consistency and robustness for downstream applications
iPSC-Lung Progenitor Cells
Identity:
- High-purity lung progenitor cells (≥70% CPM+/NKX2.1+) generated in a controlled bioreactor system
- Display physiologically relevant gene expression and functionality for developmental and disease modeling studies
- Highly suitable for applications in respiratory drug discovery, toxicity testing and regenerative medicine research
|
Identity Markers |
≥ 70% CPM+/NKX2.1+ |
|
Size |
≥ variable formats |
|
Quality Control |
Cell count, Viability, Identity (FACS), Mycoplasma, Expansion |
|
Format |
Cryopreserved cells |
|
Donor |
Female |
|
Reprogramming method |
Non-viral |
|
Shipping conditions |
Dry shipper, -180°C to -135°C |
|
Storge conditions |
Vapor phase of liquid nitrogen |
Specifications:
- Lung progenitor cells derived from iPSCs show robust expression of NKX2.1, a key transcription factor for lung lineage; flow cytometry demonstrates high proportions of NKX2.1+ cells (>85%), validating their progenitor identity
- Gene expression analysis confirms strong upregulation of NKX2.1 during directed differentiation from iPSCs through DE and AFE stages to LPCs; this stepwise process ensures reproducibility and lineage fidelity
- Ready-to-use for respiratory biology and drug discovery
iPSC-Alveolar Type II Cells
Identity:
- High-purity iPSC-derived alveolar type II epithelial cells (≥70% Pro-SPC+/ABCA3+) produced in scalable bioreactor system
- Express key AT2 markers (Pro-SPC, ABCA3) and retain proliferative capacity in vitro
- Functionally relevant for pulmonary disease modeling, fibrosis, drug testing and toxicity studies
|
Identity Markers |
≥ 70% CD34+/CD45+/CD43+ |
|
Size |
≥ variable formats |
|
Quality Control |
Cell count, Viability, Identity (FACS), Mycoplasma |
|
Format |
Cryopreserved cells |
|
Donor |
Female |
|
Reprogramming method |
Non-viral |
|
Shipping conditions |
Dry shipper, -180°C to -135°C |
|
Storge conditions |
Vapor phase of liquid nitrogen |
Specifications:
- Our AT2 cells show robust expansion potential, with proliferation increasing steadily over a 7-day culture period
- Flow cytometry analysis confirms high expression of Pro-SPC in the majority of cells, supporting their AT2 lineage identity
- Strong ABCA3 expression further validates the presence of lamellar body-associated phenotype characteristic of functional AT2 cells
- Functional activity is demonstrated by secretion of surfactant protein C (SPC), as detected by ELISA in culture supernatants, confirming their physiological relevance
